ERBB2 and triple-negative breast carcinoma: Within this study, 46.5% of patients had Luminal subtype tumors, 16.6% of patients had Luminal-HER2 tumors, 15.6% had HER2-rich tumors, and 17.2% had triple negative breast cancer.